ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RCUS Arcus Biosciences Inc

15.50
0.82 (5.59%)
Apr 23 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 582,461
Bid Price
Ask Price
News (1)
Day High 15.62

Low
12.95

52 Week Range

High
25.47

Day Low 14.57
Company Name Stock Ticker Symbol Market Type
Arcus Biosciences Inc RCUS NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.82 5.59% 15.50 20:00:00
Open Price Low Price High Price Close Price Prev Close
14.77 14.57 15.62 15.50 14.68
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,263 582,461 $ 15.23 $ 8,872,034 - 12.95 - 25.47
Last Trade Time Type Quantity Stock Price Currency
19:00:00 88,424 $ 15.50 USD

Arcus Biosciences (RCUS) Options Flow Summary

Overall Flow

Bullish

Net Premium

423k

Calls / Puts

166.67%

Buys / Sells

40.00%

OTM / ITM

33.33%

Sweeps Ratio

0.00%

Arcus Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.41B 90.86M - 117M -307M -3.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Arcus Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RCUS Message Board. Create One! See More Posts on RCUS Message Board See More Message Board Posts

Historical RCUS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week16.1816.6214.1014.87611,105-0.68-4.20%
1 Month16.6619.1114.1016.79596,507-1.16-6.96%
3 Months16.1120.3114.1017.35843,749-0.61-3.79%
6 Months16.0420.3112.9516.82804,953-0.54-3.37%
1 Year19.8225.4712.9518.38871,924-4.32-21.80%
3 Years35.0049.1012.9524.49852,427-19.50-55.71%
5 Years10.9749.106.3024.25680,5764.5341.29%

Arcus Biosciences Description

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Your Recent History

Delayed Upgrade Clock